A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative colitis

Trial Identifier: EFC18359
Sponsor: Sanofi
Collaborator:
Teva Branded Pharmaceutical Products R&D, LLC
Start Date: January 2026
Primary Completion Date: September 2028
Study Completion Date: April 2033
Condition: IBD

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario Toronto, Ontario, Canada, M6A 3B4
Japan Hachioji, Japan, 192-0032
Japan Kamakura, Japan, 247-0056
Japan Kobe, Japan, 650-0015
Japan Sapporo, Japan, 004-0041
Serbia Belgrade, Serbia, 11,000
Serbia Belgrade, Serbia, 11000
United States, California Coronado, California, United States, 92118
United States, Colorado Colorado Springs, Colorado, United States, 80907
United States, Florida Fort Myers, Florida, United States, 33901
United States, Florida Kissimmee, Florida, United States, 34741
United States, Florida Miami, Florida, United States, 33155
United States, Florida Tampa, Florida, United States, 33607
United States, Louisiana Baton Rouge, Louisiana, United States, 70809
United States, Louisiana Monroe, Louisiana, United States, 71291
United States, Missouri Liberty, Missouri, United States, 64068
United States, New York New York, United States, 10075
United States, North Carolina Fayetteville, North Carolina, United States, 28304
United States, Ohio Columbus, Ohio, United States, 43202
United States, Texas Tyler, Texas, United States, 75701